PTx is an integrated commercial stage biotech company focused on the development and commercialization of therapeutics that improve health and economic outcomes in the treatment of cancer. PTx's development focus spans the entire range of cancer therapy from primary treatments to supportive care. The company believes in delivering great products in support of medical teams with the purpose of creating the best possible outcomes for patients and their families.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/01/18 | $60,000,000 | Series A |
Adams Street Partners MidCap Financial Perceptive Advisors | undisclosed |
